Published by Josh White on 8th January 2025
(Sharecast News) - Cambridge Cognition announced the use of its 'CANTAB' cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia.
URL: http://www.digitallook.com/dl/news/story/34799012/...